Name:
Adduct:
Polarity:
Z:
m/z:
±:
CCS: Å2
±: %
SMI:
Type:

Make a CSV file containing information about your queries.
Then upload the CSV file below and click on "Make Queries" to view the results online
and click "Download Results" to download the entire results in one excel file.
An example of the CSV file can be found below

Download Example CSV


**Make sure the header column names are as follows**

...



Upload a CSV file

1
May, J. C. et al. Conformational Ordering of Biomolecules in the Gas Phase: Nitrogen Collision Cross Sections Measured on a Prototype High Resolution Drift Tube Ion Mobility-Mass Spectrometer. Anal. Chem. 86, 2107–2116 (2014).


2
Paglia, G. et al. Ion Mobility Derived Collision Cross Sections to Support Metabolomics Applications. Anal. Chem. 86, 3985–3993 (2014).


3
Groessl, M., Graf, S. & Knochenmuss, R. High resolution ion mobility-mass spectrometry for separation and identification of isomeric lipids. Analyst 140, 6904–6911 (2015).


4
Zhou, Z., Shen, X., Tu, J. & Zhu, Z.-J. Large-Scale Prediction of Collision Cross-Section Values for Metabolites in Ion Mobility-Mass Spectrometry. Anal. Chem. 88, 11084–11091 (2016).


5
Hines, K. M., Herron, J. & Xu, L. Assessment of altered lipid homeostasis by HILIC-ion mobility-mass spectrometry-based lipidomics. The Journal of Lipid Research 58, 809–819 (2017).


6
Bijlsma, L. et al. Prediction of Collision Cross-Section Values for Small Molecules: Application to Pesticide Residue Analysis. Anal. Chem. 89, 6583–6589 (2017).


7
Hines, K. M., Ross, D. H., Davidson, K. L., Bush, M. F. & Xu, L. Large-Scale Structural Characterization of Drug and Drug-Like Compounds by High-Throughput Ion Mobility-Mass Spectrometry. Anal. Chem. 89, 9023–9030 (2017).


8
Stow, S. M. et al. An Interlaboratory Evaluation of Drift Tube Ion Mobility–Mass Spectrometry Collision Cross Section Measurements. Anal. Chem. 89, 9048–9055 (2017).


9
Zhou, Z., Tu, J., Xiong, X., Shen, X. & Zhu, Z.-J. LipidCCS: Prediction of Collision Cross-Section Values for Lipids with High Precision To Support Ion Mobility–Mass Spectrometry-Based Lipidomics. Anal. Chem. 89, 9559–9566 (2017).


10
Zheng, X. et al. A structural examination and collision cross section database for over 500 metabolites and xenobiotics using drift tube ion mobility spectrometry. Chem. Sci. 8, 7724–7736 (2017).


11
Hines, K. M. et al. Characterization of the Mechanisms of Daptomycin Resistance among Gram-Positive Bacterial Pathogens by Multidimensional Lipidomics. mSphere 2, 99–16 (2017).


12
Lian, R. et al. Ion mobility derived collision cross section as an additional measure to support the rapid analysis of abused drugs and toxic compounds using electrospray ion mobility time-of-flight mass spectrometry. Anal. Methods 10, 749–756 (2018).


13
Mollerup, C. B., Mardal, M., Dalsgaard, P. W., Linnet, K. & Barron, L. P. Prediction of collision cross section and retention time for broad scope screening in gradient reversed-phase liquid chromatography-ion mobility-high resolution accurate mass spectrometry. Journal of Chromatography A 1542, 82–88 (2018).


14
Righetti, L. et al. Ion mobility-derived collision cross section database: Application to mycotoxin analysis. Analytica Chimica Acta 1014, 50–57 (2018).


15
Tejada-Casado, C. et al. Collision cross section (CCS) as a complementary parameter to characterize human and veterinary drugs. Analytica Chimica Acta 1043, 52–63 (2018).


16
Nichols, C. M. et al. Untargeted Molecular Discovery in Primary Metabolism: Collision Cross Section as a Molecular Descriptor in Ion Mobility-Mass Spectrometry. Anal. Chem. 90, 14484–14492 (2018).


17
Hines, K. M. & Xu, L. Lipidomic consequences of phospholipid synthesis defects in Escherichia coli revealed by HILIC-ion mobility-mass spectrometry. Chemistry and Physics of Lipids 219, 15–22 (2019).


18
Leaptrot, K. L., May, J. C., Dodds, J. N. & McLean, J. A. Ion mobility conformational lipid atlas for high confidence lipidomics. Nature Communications 1–9 (2019).


19
Blaženović, I. et al. Increasing Compound Identification Rates in Untargeted Lipidomics Research with Liquid Chromatography Drift Time–Ion Mobility Mass Spectrometry. Anal. Chem. 90, 10758–10764 (2018).


20
Vasilopoulou, C. G. et al. Trapped ion mobility spectrometry and PASEF enable in-depth lipidomics from minimal sample amounts. Nature Communications 1–11 (2020).


21
Tsugawa, H. et al. MS-DIAL 4: accelerating lipidomics using an MS/MS, CCS, and retention time atlas. bioRxiv 37, 513 (2020).


22
Poland, J. C. et al. Collision Cross Section Conformational Analyses of Bile Acids via Ion Mobility–Mass Spectrometry. Journal of the American Society for Mass Spectrometry 31, 1625–1631 (2020).


23
Dodds, J. et al. Rapid Characterization of Per- and Polyfluoroalkyl Substances (PFAS) by Ion Mobility Spectrometry−Mass Spectrometry (IMS-MS). Anal. Chem. 92, 4427-4435 (2020).


24
Celma, A. et al. Improving Target and Suspect Screening High-Resolution Mass Spectrometry Workflows in Environmental Analysis by Ion Mobility Separation. Environ. Sci. Technol. 54, 15120-15131 (2020)


25
Belova, L. et al. Ion Mobility-High-Resolution Mass Spectrometry (IM-HRMS) for the Analysis of Contaminants of Emerging Concern (CECs): Database Compilation and Application to Urine Samples. Anal. Chem. XXX, XXXX-XXXX (2021)


26
Ross, D. H., et al. High-Throughput Measurement and Machine Learning-Based Prediction of Collision Cross Sections for Drugs and Drug Metabolites. J Am Soc Mass Spectr 33, 1061–1072 (2022).


ID Name Adduct Structure m/z CCS SMI Type Z Ref CCS Type CCS method
CCSBASE_DB516A62EB Dimetridazole [M+H]+ 142.0611 116.4 CC1=NC=C(N1C)[N+](=O)[O-] small molecule 1 6 TW ?
CCSBASE_2BD39FE817 Doxycycline [M+H]+ 445.1605 197.4 C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=C(C(=O)[C@]3(C(=C2C(=O)C4=C1C=CC=C4O)O)O)C(=O)N)O)N(C)C)O small molecule 1 6 TW ?
CCSBASE_AACD49CFDB Dulcoside A [M+H]+ 789.3903 270.75 C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@@]34CC[C@H]5[C@@]6(CCC[C@@]([C@H]6CC[C@]5(C3)CC4=C)(C)C(=O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)CO)O)O)O)O)O small molecule 1 6 TW ?
CCSBASE_6646B001B3 Enrofloxacine [M+H]+ 360.1718 194.8 O=C(O)\C3=C\N(c2cc(N1CCN(CC)CC1)c(F)cc2C3=O)C4CC4 small molecule 1 6 TW ?
CCSBASE_8BECA714FC Ethirimol [M+H]+ 210.1061 150.65 CCCCC1=C(N=C(NC1=O)NCC)C small molecule 1 6 TW ?
CCSBASE_3F019173A9 Ethoprophos [M+H]+ 243.0637 149.27 CCCSP(=O)(OCC)SCCC small molecule 1 6 TW ?
CCSBASE_5FBF87A71D Fenamidone [M+H]+ 312.1165 171.15 C[C@@]1(C(=O)N(C(=N1)SC)NC2=CC=CC=C2)C3=CC=CC=C3 small molecule 1 6 TW ?
CCSBASE_593AB88BD9 Fenamiphos sulfone [M+H]+ 336.1029 179.48 CCOP(=O)(NC(C)C)Oc1ccc(c(c1)C)S(=O)(=O)C small molecule 1 6 TW ?
CCSBASE_7BC5DE9317 Fenbuconazole [M+H]+ 337.1215 182.44 C1=CC=C(C=C1)C(CCC2=CC=C(C=C2)Cl)(CN3C=NC=N3)C#N small molecule 1 6 TW ?
CCSBASE_78EC9685F1 Fenhexamid [M+H]+ 302.0709 164.82 CC1(CCCCC1)C(=O)NC2=C(C(=C(C=C2)O)Cl)Cl small molecule 1 6 TW ?
1 2 ... 187 188 189 190 191 192 193 ... 1698 1699